Dr. Kim has served as our Chief Medical Officer since 2011. From 2001 to 2012, Dr. Kim was an Assistant Professor of Medicine, Division of Endocrinology/Metabolism, at the University of California, San Diego School of Medicine. From 2008 to 2011, Dr. Kim held multiple senior-level clinical and corporate affairs positions at Orexigen Therapeutics, Inc. a publicly-traded biopharmaceutical company focused on the treatment of obesity, including Senior Vice President, Head of Obesity/Metabolic Diseases; Senior Vice President, Corporate Development; and Senior Vice President, Medical Affairs and Communications. Prior to Orexigen, from 2007 to 2008, he was Chief Medical Officer and Vice President of Medical Affairs at EnteroMedics, Inc. a publicly traded medical device company, where he oversaw all aspects of clinical affairs and successfully implemented an initial public offering as part of the executive team in 2007. Previously, from 2001 to 2007, he held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly traded biotechnology company, most recently as Executive Director, Corporate Strategy, where he managed corporate and business strategic planning spanning all commercial products, developmental drug candidates, corporate alliance partnership and manufacturing support. Dr. Kim holds an M.D. from the University of Health Sciences, The Chicago Medical School, an M.B.A from University of California, San Diego Rady School of Management and a B.S. in biology from the University of California at Los Angeles.